BRPI1004899A2 - composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac - Google Patents

composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac

Info

Publication number: BRPI1004899A2
Authority: BR; Brazil
Prior art keywords: treating; pi3k; mediated; disease; hdac
Prior art date: 2009-01-08

Application number

BRPI1004899A

Other languages

English (en)

Inventor

Changgeng Qian

Cheng-Jung Lai

Haixiao Zhai

Xiong Cai

Original Assignee

Curis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-08

Filing date

2010-01-08

Publication date

2016-04-05

2010-01-08 Application filed by Curis Inc filed Critical Curis Inc

2016-04-05 Publication of BRPI1004899A2 publication Critical patent/BRPI1004899A2/pt

2020-08-18 Publication of BRPI1004899B1 publication Critical patent/BRPI1004899B1/pt

2021-05-25 Publication of BRPI1004899B8 publication Critical patent/BRPI1004899B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BRPI1004899A 2009-01-08 2010-01-08 composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto BRPI1004899B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US14327109P	2009-01-08	2009-01-08
US61/143,271		2009-01-08
US17258009P	2009-04-24	2009-04-24
US61/172,580		2009-04-24
PCT/US2010/020495 WO2010080996A1 (en)	2009-01-08	2010-01-08	Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Publications (3)

Publication Number	Publication Date
BRPI1004899A2 true BRPI1004899A2 (pt)	2016-04-05
BRPI1004899B1 BRPI1004899B1 (pt)	2020-08-18
BRPI1004899B8 BRPI1004899B8 (pt)	2021-05-25

Family

ID=42316830

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1004899A BRPI1004899B8 (pt)	2009-01-08	2010-01-08	composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto

Country Status (25)

Country	Link
US (11)	US8367663B2 (pt)
EP (1)	EP2385832B1 (pt)
JP (3)	JP5452617B2 (pt)
KR (2)	KR20140094590A (pt)
CN (1)	CN102341108B (pt)
AU (1)	AU2010203512C1 (pt)
BR (1)	BRPI1004899B8 (pt)
CA (1)	CA2749228C (pt)
CY (1)	CY1116797T1 (pt)
DK (1)	DK2385832T3 (pt)
EA (1)	EA024252B1 (pt)
ES (1)	ES2550032T3 (pt)
HR (1)	HRP20150947T1 (pt)
HU (1)	HUE027615T2 (pt)
IL (2)	IL213976A (pt)
ME (1)	ME02230B (pt)
MX (1)	MX2011007326A (pt)
PL (1)	PL2385832T3 (pt)
PT (1)	PT2385832E (pt)
RS (1)	RS54230B1 (pt)
SG (2)	SG196815A1 (pt)
SI (1)	SI2385832T1 (pt)
SM (1)	SMT201500226B (pt)
TW (1)	TWI558710B (pt)
WO (1)	WO2010080996A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2385832T3 (pl)	2009-01-08	2016-01-29	Curis Inc	Inhibitory 3-kinazy fosfoinozytydowej z grupą wiążącą cynk
KR20120063515A (ko) *	2009-09-09	2012-06-15	아빌라 테라퓨틱스, 인크.	Ｐｉ３ 키나제 억제제 및 이들의 용도
AU2011239537A1 (en) *	2010-04-16	2012-11-15	Curis, Inc.	Treatment of cancers having K-ras mutations
EP2615092B1 (en) *	2010-09-10	2015-08-26	Hangzhou Bensheng Pharmaceutical Co., Ltd.	Heterocyclic amino berbamine derivatives, preparation method and use thereof
CN107011270A (zh) *	2010-11-16	2017-08-04	阿塞蒂隆制药公司	作为蛋白质去乙酰化酶抑制剂的嘧啶羟基酰胺化合物和其使用方法
US9045485B2 (en)	2010-12-16	2015-06-02	Convergence Pharmaceuticals Limited	ASK 1 inhibiting pyrrolopyrimidine derivatives
US9708299B2 (en)	2011-01-03	2017-07-18	Genentech, Inc.	Hedgehog antagonists having zinc binding moieties
JP2014505076A (ja) *	2011-01-27	2014-02-27	ザトラスティーズオブプリンストンユニバーシティ	抗ウイルス剤としてのｍＴＯＲキナーゼの阻害剤
WO2012118978A1 (en) *	2011-03-03	2012-09-07	The Regents Of The University Of Colorado, A Body Corporate	Methods for treating oncovirus positive cancers
KR101902325B1 (ko) *	2011-04-01	2018-09-28	쿠리스 인코퍼레이션	아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제
US20130102595A1 (en) *	2011-04-15	2013-04-25	Curis, Inc.	Treatment of cancers having k-ras mutations
EP2524918A1 (en)	2011-05-19	2012-11-21	Centro Nacional de Investigaciones Oncológicas (CNIO)	Imidazopyrazines derivates as kinase inhibitors
JP6206926B2 (ja)	2011-11-23	2017-10-04	キャンサー・リサーチ・テクノロジー・リミテッド	異常なプロテインキナーゼｃのチエノピリミジン阻害剤
EP3010586A1 (en)	2013-06-21	2016-04-27	Lupin Limited	Substituted heterocyclic compounds as crac modulators
CA2914415A1 (en)	2013-06-24	2014-12-31	Lupin Limited	Chromane and chromene derivatives and their use as crac modulators
WO2015013579A1 (en)	2013-07-26	2015-01-29	Update Pharma Inc.	Compositions to improve the therapeutic benefit of bisantrene
US9403779B2 (en)	2013-10-08	2016-08-02	Acetylon Pharmaceuticals, Inc.	Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
US9278963B2 (en)	2013-10-10	2016-03-08	Acetylon Pharmaceuticals, Inc.	Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
US10660890B2 (en)	2013-10-24	2020-05-26	National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr)	Treatment of polycystic diseases with an HDAC6 inhibitor
BR112016012561A2 (pt)	2013-12-03	2017-08-08	Acetylon Pharmaceuticals Inc	Combinações de inibidores da histona desacetilase e fármacos imunomoduladores
CN104725301A (zh) *	2013-12-20	2015-06-24	北京蓝贝望生物医药科技股份有限公司	一种1,2-二氢吡啶-2-酮衍生物的制备方法
US9464073B2 (en)	2014-02-26	2016-10-11	Acetylon Pharmaceuticals, Inc.	Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
JP6952602B2 (ja)	2014-07-07	2021-10-20	アセチロンファーマシューティカルズインコーポレイテッドＡｃｅｔｙｌｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	ヒストンデアセチラーゼ阻害剤による白血病の治療
KR102523430B1 (ko)	2014-08-04	2023-04-19	누에볼루션 에이/에스	염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체
CN104292242B (zh) *	2014-09-18	2017-05-17	广州必贝特医药技术有限公司	噻吩嘧啶类化合物和制剂及其制备方法和应用
WO2016087950A1 (en)	2014-12-05	2016-06-09	University of Modena and Reggio Emilia	Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
AU2014413483B2 (en) *	2014-12-11	2019-07-25	Natco Pharma Limited	7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs
KR102015826B1 (ko) *	2015-04-21	2019-08-29	구이저우 바이링 그룹 파마슈티컬 컴퍼니 리미티드	퓨리닐-n-하이드록실 피리미딘 포름아미드 유도체, 이의 제조 방법 및 용도
US10272084B2 (en)	2015-06-01	2019-04-30	Regenacy Pharmaceuticals, Llc	Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
CN105037345B (zh) *	2015-06-09	2019-01-25	天津渤海职业技术学院	抗肿瘤化合物、其制备方法和用途
CA3004534C (en) *	2015-11-23	2023-11-07	Council Of Scientific & Industrial Research	Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
JP2019515909A (ja)	2016-04-19	2019-06-13	アセチロンファーマシューティカルズインコーポレイテッドＡｃｅｔｙｌｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物
JP2019530650A (ja)	2016-08-24	2019-10-24	アークルインコーポレイテッド	アミノ−ピロロピリミジノン化合物およびその使用方法
SG11201903723RA (en) *	2016-11-02	2019-05-30	Curis Inc	Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
UA125400C2 (uk) *	2016-11-18	2022-03-02	Цистік Фіброзис Фаундейшн	Піролопіримідин як потенціатор трансмембранної провідності при муковісцидозі (cftr)
US11690847B2 (en)	2016-11-30	2023-07-04	Case Western Reserve University	Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
AU2018215678A1 (en)	2017-02-06	2019-08-22	Board Of Regents Of The University Of Texas System	Compositions and methods of modulating short-chain dehydrogenase activity
CN108623491B (zh) *	2017-03-24	2020-12-22	联化科技股份有限公司	一种卤代苯甲酰胺化合物的制备方法
CN107163061A (zh) *	2017-04-14	2017-09-15	江西科技师范大学	含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
AU2019340376B2 (en)	2018-09-11	2024-12-19	Curis Inc.	Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MA55147A (fr)	2018-11-21	2021-09-29	Univ Texas	Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte
CN114072144A (zh)	2019-02-06	2022-02-18	维瑟拉有限公司	外用磷酸肌醇3-激酶抑制剂
AR120173A1 (es) *	2019-10-09	2022-02-02	Biocryst Pharm Inc	Inhibidores del factor d del complemento para administración oral
PE20230240A1 (es)	2019-12-20	2023-02-07	Nuevolution As	Compuestos activos frente a receptores nucleares
US11447479B2 (en)	2019-12-20	2022-09-20	Nuevolution A/S	Compounds active towards nuclear receptors
EP4126875A1 (en)	2020-03-31	2023-02-08	Nuevolution A/S	Compounds active towards nuclear receptors
US11780843B2 (en)	2020-03-31	2023-10-10	Nuevolution A/S	Compounds active towards nuclear receptors
WO2022152229A1 (zh) *	2021-01-15	2022-07-21	深圳微芯生物科技股份有限公司	一类吗啉衍生物及其制备方法和应用
JP7736782B2 (ja) *	2021-03-29	2025-09-09	株式会社カネカ	（２－メチルピリミジン－５－イル）ボロン酸誘導体の製造方法
CN113754680B (zh) *	2021-09-28	2022-07-22	云白药征武科技(上海)有限公司	一种α氟代酰基哌嗪衍生物及其制备和应用
EP4410795A4 (en) *	2021-09-30	2025-10-01	Hanmi Pharmaceutical Co Ltd	PIKFYVE KINASE INHIBITOR
KR20250005373A (ko)	2022-04-22	2025-01-09	버텍스 파마슈티칼스 인코포레이티드	통증 치료를 위한 헤테로아릴 화합물
CN117865979A (zh) *	2024-01-04	2024-04-12	广州必贝特医药股份有限公司	噻吩嘧啶类化合物的晶型及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5369108A (en) *	1991-10-04	1994-11-29	Sloan-Kettering Institute For Cancer Research	Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) *	1992-04-03	1996-03-26	The Upjohn Company	Pharmaceutically active bicyclic-heterocyclic amines
US6777217B1 (en) *	1996-03-26	2004-08-17	President And Fellows Of Harvard College	Histone deacetylases, and uses related thereto
WO2000022551A1 (en) *	1998-10-13	2000-04-20	Chris Cheah	Method and system for controlled distribution of information over a network
US6608053B2 (en) *	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
EP1277738B1 (en)	2000-04-27	2011-03-30	Astellas Pharma Inc.	Condensed heteroaryl derivatives
CN100503599C (zh)	2002-03-13	2009-06-24	詹森药业有限公司	作为组蛋白脱乙酰酶的新颖抑制剂的羰基氨基衍生物
AU2003218736B2 (en)	2002-03-13	2009-01-08	Janssen Pharmaceutica N.V.	New inhibitors of histone deacetylase
KR20040090978A (ko)	2002-03-13	2004-10-27	얀센 파마슈티카 엔.브이.	히스톤 디아세틸라제의 신규한 저해제로서의 설포닐-유도체
US7767679B2 (en)	2002-03-13	2010-08-03	Janssen Pharmaceutica N.V.	Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
AU2003255845A1 (en)	2002-08-22	2004-03-11	Piramed Limited	Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
SI1591446T1 (sl) *	2003-01-29	2013-07-31	Takeda Pharmaceutical Company Limited	Tienopiridinske spojine in njihova uporaba
EP1750727A2 (en) *	2004-04-23	2007-02-14	Exelixis, Inc.	Kinase modulators and methods of use
US7218492B2 (en) *	2004-09-17	2007-05-15	Electronic Polymers, Inc.	Devices and systems for electrostatic discharge suppression
JP4862654B2 (ja)	2004-10-08	2012-01-25	アステラス製薬株式会社	芳香環縮合ピリミジン誘導体
GB0423653D0 (en)	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
US20080213399A1 (en)	2005-02-03	2008-09-04	Topotarget Uk Limited	Combination Therapies Using Hdac Inhibitors
DK1885710T3 (en)	2005-05-18	2015-11-23	Janssen Pharmaceutica Nv	SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
US7731753B2 (en) *	2005-09-01	2010-06-08	Spinal Kinetics, Inc.	Prosthetic intervertebral discs
JP5021660B2 (ja) *	2005-10-24	2012-09-12	バイオメット・３アイ・エルエルシー	歯科用インプラント構成要素を製造するための方法
JP2007151829A (ja) *	2005-12-05	2007-06-21	Bridgestone Sports Co Ltd	ゴルフクラブヘッド
CN101370790B (zh)	2006-01-19	2015-10-21	詹森药业有限公司	作为组蛋白去乙酰化酶抑制剂的吡啶和嘧啶衍生物
ES2376121T3 (es)	2006-01-19	2012-03-09	Janssen Pharmaceutica, N.V.	Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa.
CA2633100C (en)	2006-01-19	2014-12-09	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
PT2041139E (pt) *	2006-04-26	2012-01-13	Hoffmann La Roche	Compostos farmacêuticos
BRPI0710866A2 (pt)	2006-04-26	2012-08-14	Hoffmann La Roche	compostos farmacÊuticos
CN101511840A (zh)	2006-04-26	2009-08-19	吉宁特有限公司	磷酸肌醇3-激酶抑制剂化合物及其使用方法
WO2007129161A2 (en)	2006-04-26	2007-11-15	F. Hoffmann-La Roche Ag	Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
EP2018366A4 (en)	2006-05-16	2010-08-04	Univ Mcgill	HYBRID MOLECULES WITH MIXED VITAMIN D RECEPTOR AGONISM AND HISTONDEACETYLASE RESISTANT PROPERTIES
US7928136B2 (en) *	2006-09-11	2011-04-19	Curis, Inc.	Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
US20080161320A1 (en) *	2006-09-11	2008-07-03	Xiong Cai	Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US7547781B2 (en) *	2006-09-11	2009-06-16	Curis, Inc.	Quinazoline based EGFR inhibitors containing a zinc binding moiety
US8604044B2 (en) *	2006-09-11	2013-12-10	Curis, Inc.	Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033744A2 (en) *	2006-09-11	2008-03-20	Curis, Inc.	Dna methyl transferase inhibitors containing a zinc binding moiety
US7888361B2 (en) *	2006-09-11	2011-02-15	Curis, Inc.	Tyrosine kinase inhibitors containing a zinc binding moiety
EP2061469B8 (en) *	2006-09-11	2014-02-26	Curis, Inc.	Quinazoline based egfr inhibitors
SG174772A1 (en) *	2006-09-11	2011-10-28	Curis Inc	Multi-functional small molecules as anti-proliferative agents
SI2343286T1 (sl)	2006-10-28	2015-05-29	Methylgene Inc.	Derivati dibenzo(b,f)(1,4) oksazepina kot inhibitorji histonske deacetilaze
ES2544082T3 (es) *	2006-12-07	2015-08-27	F. Hoffmann-La Roche Ag	Compuestos inhibidores de fosfoinosítido 3-quinasa y métodos de uso
KR101507182B1 (ko)	2006-12-07	2015-03-30	제넨테크, 인크.	포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
CA2677651A1 (en)	2007-02-15	2008-08-21	Novartis Ag	Combinations of therapeutic agents for treating cancer
US20080234332A1 (en) *	2007-03-20	2008-09-25	Xiong Cai	Raf kinase inhibitors containing a zinc binding moiety
TW200922590A (en) *	2007-09-10	2009-06-01	Curis Inc	VEGFR inhibitors containing a zinc binding moiety
WO2009036066A1 (en)	2007-09-10	2009-03-19	Curis, Inc.	Vegfr inhibitors containing a zinc binding moiety
WO2009036020A1 (en)	2007-09-10	2009-03-19	Curis, Inc.	Mek inhibitors containing a zinc binding moiety
TW200922564A (en) *	2007-09-10	2009-06-01	Curis Inc	CDK inhibitors containing a zinc binding moiety
WO2009036057A1 (en)	2007-09-10	2009-03-19	Curis, Inc.	Antiproliferative agents containing a zinc binding moiety
KR101584823B1 (ko)	2007-09-12	2016-01-22	제넨테크, 인크.	포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법
WO2009042646A1 (en)	2007-09-24	2009-04-02	Curis, Inc.	Anti-proliferative agents
JP2011500702A (ja) *	2007-10-16	2011-01-06	ワイス・エルエルシー	チエノピリミジンおよびピラゾロピリミジン化合物ならびにｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのその使用
WO2009055730A1 (en)	2007-10-25	2009-04-30	Genentech, Inc.	Process for making thienopyrimidine compounds
WO2009058895A1 (en)	2007-10-30	2009-05-07	Syndax Pharmaceuticals, Inc.	Administration of an inhibitor of hdac and an mtor inhibitor
WO2009086012A1 (en)	2007-12-20	2009-07-09	Curis, Inc.	Aurora inhibitors containing a zinc binding moiety
JP2011525535A (ja)	2008-06-24	2011-09-22	武田薬品工業株式会社	ＰＩ３Ｋ／ｍＴＯＲ阻害剤
WO2009155659A1 (en)	2008-06-27	2009-12-30	The University Of Queensland	Combination therapy
PL2385832T3 (pl)	2009-01-08	2016-01-29	Curis Inc	Inhibitory 3-kinazy fosfoinozytydowej z grupą wiążącą cynk
BRPI1006189A2 (pt)	2009-03-12	2020-08-18	Genentech Inc	uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
US20110086837A1 (en) *	2009-10-12	2011-04-14	Genentech, Inc.	Combinations of a pi3k inhibitor and a mek inhibitor
AU2011239537A1 (en) *	2010-04-16	2012-11-15	Curis, Inc.	Treatment of cancers having K-ras mutations
KR101902325B1 (ko)	2011-04-01	2018-09-28	쿠리스 인코퍼레이션	아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제
US20130102595A1 (en)	2011-04-15	2013-04-25	Curis, Inc.	Treatment of cancers having k-ras mutations

2010
- 2010-01-08 PL PL10729566T patent/PL2385832T3/pl unknown
- 2010-01-08 SG SG2014002737A patent/SG196815A1/en unknown
- 2010-01-08 US US12/684,594 patent/US8367663B2/en active Active
- 2010-01-08 KR KR1020147014945A patent/KR20140094590A/ko not_active Withdrawn
- 2010-01-08 EA EA201101053A patent/EA024252B1/ru unknown
- 2010-01-08 MX MX2011007326A patent/MX2011007326A/es active IP Right Grant
- 2010-01-08 ES ES10729566.9T patent/ES2550032T3/es active Active
- 2010-01-08 RS RS20150596A patent/RS54230B1/sr unknown
- 2010-01-08 ME MEP-2015-149A patent/ME02230B/me unknown
- 2010-01-08 WO PCT/US2010/020495 patent/WO2010080996A1/en not_active Ceased
- 2010-01-08 CA CA2749228A patent/CA2749228C/en active Active
- 2010-01-08 JP JP2011545452A patent/JP5452617B2/ja active Active
- 2010-01-08 DK DK10729566.9T patent/DK2385832T3/en active
- 2010-01-08 EP EP10729566.9A patent/EP2385832B1/en active Active
- 2010-01-08 PT PT107295669T patent/PT2385832E/pt unknown
- 2010-01-08 AU AU2010203512A patent/AU2010203512C1/en active Active
- 2010-01-08 KR KR1020117018181A patent/KR101430424B1/ko active Active
- 2010-01-08 TW TW099100348A patent/TWI558710B/zh active
- 2010-01-08 BR BRPI1004899A patent/BRPI1004899B8/pt active IP Right Grant
- 2010-01-08 HR HRP20150947TT patent/HRP20150947T1/hr unknown
- 2010-01-08 HU HUE10729566A patent/HUE027615T2/en unknown
- 2010-01-08 SI SI201031013T patent/SI2385832T1/sl unknown
- 2010-01-08 SG SG2011049848A patent/SG172908A1/en unknown
- 2010-01-08 CN CN201080010977.1A patent/CN102341108B/zh active Active
2011
- 2011-04-01 US US13/078,769 patent/US8461157B2/en active Active
- 2011-07-07 IL IL213976A patent/IL213976A/en active IP Right Grant
2013
- 2013-05-13 US US13/892,373 patent/US8906909B2/en active Active
- 2013-12-27 JP JP2013271719A patent/JP5762520B2/ja active Active
2014
- 2014-11-12 US US14/539,327 patent/US9725461B2/en active Active
2015
- 2015-03-12 IL IL237727A patent/IL237727A0/en unknown
- 2015-06-09 JP JP2015116323A patent/JP2015187145A/ja not_active Withdrawn
- 2015-09-24 SM SM201500226T patent/SMT201500226B/xx unknown
- 2015-10-13 CY CY20151100919T patent/CY1116797T1/el unknown
2017
- 2017-06-29 US US15/637,448 patent/US10336770B2/en active Active
2019
- 2019-05-29 US US16/425,316 patent/US10676482B2/en active Active
2020
- 2020-05-12 US US15/930,103 patent/US10894795B2/en active Active
- 2020-12-23 US US17/132,399 patent/US11261195B2/en active Active
2022
- 2022-01-27 US US17/585,701 patent/US11597732B2/en active Active
2023
- 2023-01-13 US US18/097,038 patent/US20230227467A1/en not_active Abandoned
2024
- 2024-08-23 US US18/813,989 patent/US20250230169A1/en active Pending

Also Published As

Publication number	Publication date
US10894795B2 (en)	2021-01-19
IL213976A (en)	2015-03-31
PT2385832E (pt)	2015-11-02
TWI558710B (zh)	2016-11-21
MX2011007326A (es)	2011-10-19
BRPI1004899B1 (pt)	2020-08-18
AU2010203512B2 (en)	2013-03-14
ME02230B (me)	2016-02-20
US20120088764A1 (en)	2012-04-12
EP2385832B1 (en)	2015-07-15
SMT201500226B (it)	2015-10-30
JP2015187145A (ja)	2015-10-29
EP2385832A1 (en)	2011-11-16
KR20110112404A (ko)	2011-10-12
US11597732B2 (en)	2023-03-07
IL213976A0 (en)	2011-08-31
RS54230B1 (sr)	2015-12-31
US20250230169A1 (en)	2025-07-17
SG196815A1 (en)	2014-02-13
CA2749228C (en)	2016-05-17
US9725461B2 (en)	2017-08-08
JP2012514650A (ja)	2012-06-28
HRP20150947T1 (hr)	2015-10-09
US10336770B2 (en)	2019-07-02
PL2385832T3 (pl)	2016-01-29
KR20140094590A (ko)	2014-07-30
US10676482B2 (en)	2020-06-09
TW201030009A (en)	2010-08-16
HUE027615T2 (en)	2016-10-28
DK2385832T3 (en)	2015-09-21
CY1116797T1 (el)	2018-03-07
CA2749228A1 (en)	2010-07-15
US20200339593A1 (en)	2020-10-29
US20100222343A1 (en)	2010-09-02
KR101430424B1 (ko)	2014-08-14
US20210214370A1 (en)	2021-07-15
US20230227467A1 (en)	2023-07-20
US20170362251A1 (en)	2017-12-21
JP2014058571A (ja)	2014-04-03
US20140155595A1 (en)	2014-06-05
EP2385832A4 (en)	2012-07-25
US11261195B2 (en)	2022-03-01
US8367663B2 (en)	2013-02-05
JP5452617B2 (ja)	2014-03-26
ES2550032T3 (es)	2015-11-04
CN102341108A (zh)	2012-02-01
WO2010080996A1 (en)	2010-07-15
HK1164113A1 (en)	2012-09-21
US20190352310A1 (en)	2019-11-21
JP5762520B2 (ja)	2015-08-12
CN102341108B (zh)	2015-05-27
SG172908A1 (en)	2011-08-29
US8461157B2 (en)	2013-06-11
SI2385832T1 (sl)	2015-10-30
US20220402934A1 (en)	2022-12-22
AU2010203512C1 (en)	2013-10-17
EA024252B1 (ru)	2016-08-31
BRPI1004899B8 (pt)	2021-05-25
AU2010203512A1 (en)	2011-08-11
US8906909B2 (en)	2014-12-09
EA201101053A1 (ru)	2012-02-28
IL237727A0 (en)	2015-05-31
US20150203509A1 (en)	2015-07-23

Publication	Publication Date	Title
BRPI1004899A2 (pt)	2016-04-05	composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac
BR112012028530A2 (pt)	2017-12-19	composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno
BR112013026341A2 (pt)	2019-09-24	composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
BR112014011671A2 (pt)	2017-05-30	composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112015003332A2 (pt)	2017-09-26	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112012004333A2 (pt)	2015-09-08	composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BR112015003398A2 (pt)	2018-04-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112014004181A2 (pt)	2017-06-13	composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
BR112013025340A2 (pt)	2016-12-13	composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado com pi3k num indivíduo necessitado, método para tratar doença mediada por hdac e método para tratar tanto doenças mediadas por pi3k como por hdac
BR112015001098A2 (pt)	2017-08-08	composto, composição farmacêutica e método para o tratamento de uma condição de doença.
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI1008974A2 (pt)	2017-06-06	composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
BRPI0912111A2 (pt)	2015-10-06	composto, composição farmacêutica, método para tratar, controlar ou prevenir uma doença ou distúrbio, e, forma de dosagem unitária única
BR112014010186A2 (pt)	2017-05-02	formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
BRPI0815387A2 (pt)	2017-05-23	composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição
BRPI0822398A2 (pt)	2014-11-18	Forma sólida, mistura, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou distúrbio e um câncer
BR112013020352A2 (pt)	2017-08-08	composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112012018947A8 (pt)	2017-12-19	composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BRPI0905733A2 (pt)	2015-12-01	"composição, formulação farmacêutica, método para tratamento de câncer positivo para her2 e método pára a produção de uma composição farmacêutica"
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BR112014003296A2 (pt)	2017-03-14	composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-05-21	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-08-20	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-01-21	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-05-19	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-08-18	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2022-08-02	B25G	Requested change of headquarter approved	Owner name: CURIS, INC. (US)